RxDoctor Payments Data

Hamid Fadavi, DO

Interventional Pain Medicine · Mission Viejo, CANPI 1477787034

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $13,956 of the $19,463 with a category attached, or 71.7%. 47 manufacturers reported payments, led by AbbVie at 45.6% of the total.

$19,463in general payments, 2019–2025

Across 720 payments — averaging $27.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$9K
  • Medtronic$2K
  • Boston Scientific$1K
  • Nevro Corp.$940
  • Curonix LLC$833
  • Collegium Pharmaceutical, Inc.$589
  • plus $5K from 41 others

What the payments were for

  • Consulting fees$5,10026%
  • Travel & lodging$3392%
  • Food & beverage$13,95672%
  • Education$670%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,463 in reported general payments places this provider in the 85th percentile of 188 interventional pain medicine providers in California.

See all interventional pain medicine providers in California

Medicare billing

Part B allowed, 2024
$349,953
Medicare patients
323
Services billed
21,441

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MovantikNaloxegol Oxalate48$19,204
Diclofenac Sodium50$14,053
OxycontinOxycodone Hcl19$10,881
Emgality SyringeGalcanezumab-Gnlm11$7,817
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen406$6,975
Buprenorphine30$6,825
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen259$5,479
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl45$4,376
Gabapentin297$4,066
Fentanyl15$3,641
Lidocaine49$3,617
Oxycodone Hcl172$1,745
Pregabalin110$1,291
Cyclobenzaprine Hcl81$973
Methocarbamol105$891

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Redhill Biopharma Inc.Movantik$16$19,20448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 188 interventional pain medicine providers in California.

Other interventional pain medicine in Mission Viejo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →